StreetSpread · Technology · Kalshi

Will the FDA approve intismeran autogene (V940/mRNA-4157) with pembrolizumab (KEYTRUDA) for adjuvant treatment of completely resected stage IIB-IV melanoma before Oct 1, 2027?

Technology Closes October 1, 2027 Kalshi

Kalshi's current ask is 74¢ for YES on this contract (74% implied). Closes October 1, 2027 (~320 days).

Live price

SideCentsImpliedVolume
Kalshi (yes ask)74¢74%$1K
Kalshi (yes bid)65¢65%—
Trade on Kalshi →
Don't just watch the number
Today's top 5 gaps →The five most actionable spreads across every venue right now — free. Ask Ace about this market →3 free questions with the AI analyst — in the app. Track it live →Real-time spreads, price history, and alerts on your phone.
Get the app →Live on the App Store — every venue priced side by side, in your pocket.
StreetSpread aggregates real-time odds across Kalshi, Polymarket, DraftKings, FanDuel, BetMGM, Caesars, and Fanatics. Prices refresh about every two minutes. Back to live tracker · Get the app.

Follow us: X (@thestreetspread) · Instagram (@thestreetspread) · LinkedIn